Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck ’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C

Dateline City: KENILWORTH, N.J. Study Evaluated VA Population with High Incidence of Co-MorbiditiesKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER®in the U.S. Department of Veterans Affairs (VA) healthcare system.Language: EnglishContact: Merck& Co., Inc.Media:Doris Li, 908-740-1903orMichael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK ZEPATIER Source Type: news